MIM
MLYS icon

Monashee Investment Management’s Mineralys Therapeutics MLYS Stock Holding History

Monashee Investment Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-112,457
Closed -$1.79M – 74
2025
Q1 		$1.79M Buy
+112,457
New +$1.29M 0.21% 41
2023
Q2 		– Sell
-110,000
Closed -$1.72M – 83
2023
Q1 		$1.72M Buy
+110,000
New +$1.85M 0.48% 38

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Monashee Investment Management's MLYS Position: Q2 2025 in Review

Monashee Investment Management sold out of Mineralys Therapeutics (MLYS) in Q2 2025, closing a stake of 112,457 shares — an estimated $1.79M sold.

Monashee Investment Management first reported a position in MLYS in Q1 2023 and held it in 2 quarters. The position peaked at $1.79M in Q1 2025. 165 funds tracked by Wall St. Rank hold MLYS as of Q2 2025.

  • Monashee Investment Management reported no remaining Mineralys Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Monashee Investment Management sold 112,457 Mineralys Therapeutics shares in Q2 2025, an estimated $1.79M.
  • Monashee Investment Management first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 2 quarters.
  • Monashee Investment Management's Mineralys Therapeutics position peaked at $1.79M in Q1 2025.
  • 165 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2025.

Based on Monashee Investment Management's 13F filing for Q2 2025, filed 11 Aug 2025.